AstraZeneca announces WAYPOINT trial met both co-primary endpoints
Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and ...
GlobalData on MSN9d
AiCuris commences Phase I trial of AIC468 for BK virus treatment
AiCuris Anti-infective Cures has launched a first-in-human Phase I trial of AIC468, an antisense oligonucleotide designed to ...
Allakos Runs Up Into A Near-Term Catalyst
Allakos shifted focus to AK006 in 2024 after lirentelimab's failure in phase 2 trials for atopic dermatitis and CSU. Read why ...
ophthalmologytimes3d
Formosa Pharmaceuticals announces top-line results from Chinese trial evaluating APP13007
Formosa Pharmaceuticals has announced the completion and top-line results from CPN-303, a phase 3 clinical study of APP13007 ...
freedommag9d
Drug Manufacturers Sponsor Drug Trials, Ignore Negative Results
A review of published psychiatric drug trials shows that successful outcomes are more often published, and unsuccessful ...
Hosted on MSN5d
Esketamine Also Effective Without Adjunctive Antidepressant
Approved in March 2019, esketamine is currently indicated for use alongside an oral antidepressant for treatment-resistant ...
TEZSPIRE MET BOTH CO-PRIMARY ENDPOINTS IN PHASE 3 TRIAL FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
Amgen (NASDAQ:AMGN) and AstraZeneca today announced positive top-line results from the Phase 3 WAYPOINT trial in patients ...
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for ...
AstraZeneca/Amgen's Asthma Drug Aces Late-Stage Study In Patients With Chronic Rhinosinusitis
AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.
pulmonologyadvisor1d
Rodatristat Ethyl in PAH Linked to Adverse Effects on PVR and Cardiac Function
In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.
manilatimes12d
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
The CardiAMP HF Trial is assessing the safety and effectiveness of the CardiAMP ® Cell Therapy System for HFrEF, with the potential to reduce all cause death, future hospitalizations, enhance ...